FIT screening

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. The good news is that CRC incidence and mortality can be reduced significantly if detected early enough.

Faecal immunochemical tests (FIT) are non-invasive and can detect blood in stool invisible to the naked eye. Due to its simplicity, FIT is currently considered the best non-invasive test for CRC screening.

Invest a little time in your own health by taking the FIT to prevent or detect colon cancer early on.
For further information, please visit our ‘FIT for screening’ website


Clinical evaluation of Sysmex Inostics’ plasma NGS liquid biopsy technology to complement mammography when screening for early stage breast cancer presented at the 2018 ASCO annual meeting Sysmex Establishes Subsidiary in Egypt and Begins Conducting Direct Sales and Services Sysmex, the Foundation for Biomedical Research and Innovation at Kobe, and Kyoto University Begin Joint Research on Technologies for Diagnosing Immunological Diseases CytoCell und weitere Oxford Gene Technology Produkte bei Sysmex erhältlich Die neue Ausgabe unseres Kundenmagazins Xtra ist da! Sysmex Launches New Products in Its System for the Testing of Cancer Lymph Node Metastasis Using the OSNA™ Method: Gene Amplification Detector RD-200 and LYNOAMP™ CK19 Sysmex Group Formulates New Long-Term Management Goals Sysmex Announces “Sysmex Eco-Vision 2025” Sysmex to Establish Bio-Diagnostic Reagent Center Neuer Sysmex Slogan "Lighting the way with diagnostics" Sysmex Employee to Receive the “Medal with Purple Ribbon,” a Spring 2018 Medal of Honor Neuer Sysmex Slogan “Lighting the way with diagnostics” Sysmex to Launch JICA Project in the Republic of Ghana: "Collaboration Program for Disseminating Automated Urinalysis Diagnosis Technology” Sysmex Europe GmbH to Transfer Management of All European Installations of The DigniCap Scalp Cooling System Back to Dignitana AB Sysmex Launches Caresphere™, a New Network Solution II Международный междисциплинарный научно-практический Форум-выставка «ЛАБОРАТОРНАЯ МЕДИЦИНА: СОВРЕМЕННЫЕ ТЕХНОЛОГИИ И ДИАГНОСТИКА» Школа Гематолога в Перми Advanced Medical Care Approval Received for Multiplex Gene Panel Testing to Advancing Personalized Medicine Sysmex Formulates New Corporate Message:“Lighting the way with diagnostics” Bundestagsabgeordnete besucht Sysmex in Norderstedt «Конференция для специалистов лабораторной службы Липецкой области» Школа гемостаза в Ростове-на-Дону Japan’s first-ever industry-academia alliance to realize the development of innovative medicine in Japan OncoBEAM™ RAS CRC liquid biopsy test now reimbursed in Germany by BARMER Sysmex to Be Special Sponsor of the Kobe Marathon 2018 Sysmex feiert 50-jähriges Jubiläum Sysmex feiert 50-jähriges Jubiläum Sysmex feiert 50-jähriges Jubiläum Sysmex Middle East in Medlab exhibition 5-8 February 2018 in Dubai- UAE мероприятие IV Медицинский форум «Актуальные вопросы совершенствования медицинской помощи. Ильменские встречи» Школа Гемостаза «Тромботические и геморрагические осложнения в акушерстве, гинекологии и неонатологии» A fondo: Comparación de los resultados obtenidos en los análisis de biopsias líquidas OncoBEAM RAS CRC e Idylla ctKRAS para la detección de la mutación KRAS presentados en la reunión GI de la ASCO en 2018 Podrobná zpráva: Porovnání výkonu testů likvidní biopsie OncoBEAM RAS CRC a Idylla ctKRAS prezentované na konferenci ASCO GI 2018 Nový e-shop protilátek Leistungsvergleich der Liquid Biopsy-Verfahren OncoBEAM RAS CRC und Idylla ctKRAS zum Nachweis von KRAS-Mutationen auf der ASCO-GI-Konferenz 2018 vorgestellt In depth: Performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS liquid biopsy testing for KRAS mutation detection presented at ASCO GI 2018
See the scalability of XN
Enjoy our Media Centre
  • All
  • Documents
  • Podcast
  • Images
  • Videos
See our collection
See the scalability of XN